PrimeRFP SCOUT · Federal Contract Recompete Brief

75N92025P00384 — SMALL RNA CHARACTERIZATION OF URINARY EXOSOMES, NEW PO

SMALL RNA CHARACTERIZATION OF URINARY EXOSOMES, NEW PO is a federal NONE award for Department of Health and Human Services (HHS) held by NORGEN BIOTEK CORP. Estimated value $157K ($157K obligated). Current period of performance ends Sep 18, 2026. Last award drew 4 bidders. Place of performance: BETHESDA MD. Related solicitation 75N92025Q00112.

$157K
Estimated Value
Sep 18, 2026
PoP End / Expires
4
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

NORGEN BIOTEK CORP holds $54K across 3 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 4 offers. Set-aside status: NONE. Recompete timing centers on the Sep 18, 2026 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75N92025P00384
AgencyDepartment of Health and Human Services (HHS)
IncumbentNORGEN BIOTEK CORP
CAGEL7887
UEISB5ZH66FTV27
NAICS541380

No full NAICS 541380 intel page yet. Browse NAICS intelligence

PSCQ301
Place of performanceBETHESDA MD
Pricing typeFirm Fixed Price
Extent competedCompeted Under SAP
Related solicitation75N92025Q00112
PoP startSep 19, 2025
PoP end (current)Sep 18, 2026
Obligated$157K
Current value$157K
Potential value$157K

SMALL RNA CHARACTERIZATION OF URINARY EXOSOMES, NEW PO

Recompete timing

Public
Expiring in 29 days

Current PoP ends Sep 18, 2026 (29 days remaining). Agencies typically plan 12–18 months ahead — at 1.0 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

NORGEN BIOTEK CORP$54K obligated across 3 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$54K · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75N92025P00384
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open NORGEN BIOTEK CORP’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N92025P00384?

75N92025P00384 (SMALL RNA CHARACTERIZATION OF URINARY EXOSOMES, NEW PO) is a Department of Health and Human Services (HHS) award with an estimated value of $157K, currently held by NORGEN BIOTEK CORP. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N92025P00384?

NORGEN BIOTEK CORP is the incumbent with $54K across 3 related awards in SCOUT’s public footprint. The current period of performance ends Sep 18, 2026.

When does 75N92025P00384 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 18, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N92025P00384

SCOUT Signal

August 2026

One VA health contract was 35% of civilian federal obligations in July.

Meanwhile VA's service-disabled veteran-owned contract actions fell 41.8%. The same agency, the same month, the large-vendor lane expanding while the small-business lane contracted. Figures are civilian-agency obligations through 2026-07-31; DoD FPDS for this window is labeled incomplete.

This issue is the whole civilian market. Your capture plan isn't.

Read the August 2026 issue →